Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IoGen for periodic breast pain in fibrocystic breast disease
NCT00237523Phase 3Unknown
- Sponsor
- Symbollon Pharmaceuticals, Inc.
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in fibrocystic breast changes comparing IoGen with Placebo (2 arms). Primary endpoint: Total clinical breast pain per menstrual cycle at 6 months. Status: unknown.
02
Drugs
IoGen
03
Conditions
fibrocystic breast changes
Beyond the preview
Go deeper on NCT00237523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00237523.